Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTIS2023-507059-32-00
CTIS2023-507059-32-00RecruitingPhase 1

VMX-C001-03

VarmX B.V.0 sites48 target enrollmentStarted: September 20, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Sponsor
Enrollment
48
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 65+ (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor
VarmX B.V.

Similar Trials

Active, not recruiting
Phase 1
A study to investigate VMX-C001 in healthy volunteers.To restore coagulation in patients taking DOACs who are experiencing bleeding or who require reversal of anticoagulation prior to urgent surgery.MedDRA version: 20.0Level: PTClassification code: 10009773Term: Coagulation factor X level Class: 100000004848
CTIS2024-514339-87-00VarmX B.V.12
Active, not recruiting
Phase 1
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of three dose levels of the OVX033 vaccine, after intramuscular administration in healthy subjects aged 18-49 years
CTIS2023-506396-94-00Osivax48
Recruiting
Phase 1
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)
CTIS2024-513329-22-00Kyverna Therapeutics Inc.32
Recruiting
Phase 1
A PHASE-1, FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND FOOD EFFECT OF ORALLY ADMINISTERED VENT-03 IN HEALTHY VOLUNTEERSupus erythematosusMedDRA version: 21.1Level: LLTClassification code: 10025139Term: Lupus erythematosus systemic Class: 10028395
CTIS2023-507504-31-00Ventus Therapeutics U.S. Inc.72
Active, not recruiting
Phase 1
MK-1403 Single Dose Formulation PK StudyMedDRA version: 20.0Level: LLTClassification code: 10003601Term: Atherosclerosis Class: 10047065Atherosclerosis
CTIS2023-507984-20-00Merck Sharp & Dohme LLC16